Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-451840 in induced malaria infection
NCT02223871Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACT-451840 in Falciparum malaria (PF), sponsored by Idorsia. Primary endpoint: Drug-specific Parasite Reduction Ratio over 48 hours. Started Jun 2014; status: completed.
02
Drugs
ACT-451840
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on NCT02223871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223871.